Zoster vaccine

Zoster vaccine

Recombinant vaccine to reduce the incidence of herpes zoster and to alleviate the postherpetic neuralgia.

R&D Goals

Shingles is a painful skin rash, often with blisters. It is also called Herpes Zoster, or just Zoster.

Shingles is due to a reactivation of varicella zoster virus (VZV) within a person's body. Chickenpox is due to an initial infection with VZV. Once chickenpox has resolved, the virus may remain inactive in nerve cells and reactivated to cause shingles. Risk factors for reactivation include older age, poor immune function.

The current zoster vaccine (Zostavax) needs to be improved, since the efficacy is reported 50% in clinical trials. Also some people in immune compromised state or pregnant women should not get this live attenuated vaccine due to the risk of infection.

Features of CVI-VZV-001
  • CVI-VAV-001 is an adjuvanted recombinant vaccine containing recombinant gE antigen of varicella-zoster virus and the adjuvant L-pampo.

  • Higher vaccine efficacy is expected by enhancing the cellular immune responses with adjuvant L-pampo, especially in the older population. This vaccine can also reduce pain of postherpetic neuralgia.

  • We have achieved high production yield and production scale-up of the recombinant antigen. As a result, low cost supply is possible.